title: Three year clinical outcomes with zotarolimus (Endeavor) drug-eluting stents in an unrestricted contemporary practice.
authors.affiliation: Room 341, 40 Ruskin Ave, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Canada K1Y4W7.
authors.forename: Katie
authors.initials: K
authors.lastname: Giles
authors.forename: Benjamin
authors.initials: B
authors.lastname: Hibbert
authors.forename: Luke
authors.initials: L
authors.lastname: Drzymala
authors.forename: Marika
authors.initials: M
authors.lastname: Armstrong
authors.forename: Derek
authors.initials: D
authors.lastname: So
authors.forename: Michel R
authors.initials: MR
authors.lastname: Le May
authors.forename: Christopher
authors.initials: C
authors.lastname: Glover
mesh_terms: D000368:Aged; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology; D015331:Cohort Studies; D054855:Drug-Eluting Stents / Q000639:trends*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C489443:zotarolimus; D020123:Sirolimus
keywords: Endeavor; Stent thrombosis; Zotarolimus